CTRI/2022/01/039662Not yet recruitingPhase 2
A Comparative Phase 2 Clinical Study To Evaluate Efficacy Of Tilakusumadilepa And Vipadikahar Lepa In The Management Of Vipadika With Special Rereference To Palmo-Plantar Psoriasis.
Ayurved Seva Sangh Ayurved Mahavidyalaya Nashik1 site in 1 country70 target enrollmentStarted: January 2, 2022Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- REDUCTION IN SIGN AND SYMPTOMS OF VIPADIKA
Study Overview
Brief Summary
The diagnosed patients of Vipadika will be treated for group A with Tilakusumadilepa mentioned in Bhaishajya Ratnawali 125 gms for 30 days used twice a day as topical application.The comparative drug for group B with Vipadikahar lepa mentioned in Sahastrayog will be given 125 gms for 30 days used twice a day as topical application.Assessement criteria will be those patients with classical signs and symptoms of vipadika -panipadsphutan vedana, Kandu, Khara sparshata,strava.Patients with other skin diseases Like Ringworm, scabies,Eczema etc will be excluded from study.The patients will be selected from kayachikitsa opd no 13..
Study Design
- Study Type
- Interventional
- Allocation
- Computer generated randomization
- Masking
- Open Label
Eligibility Criteria
- Ages
- 18.00 Year(s) to 60.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Patients with classical signs and symptoms of vipadika.
- •panipadsphutan, vedana Kandu Kharasparshata Strava Patients of Age group.
- •60 years of Age. Patients willing to participate in the study , who give written consent.
Exclusion Criteria
- •Patients below 18 & above 60 years of age.
- •Patients with other uncontrolled systemic disorders like DM/ HTN/Cardiac disorders/leprosy/Tuberculosis/Malignancy will be excluded.
- •Patients with other skin diseases Like Ringworm, scabies, Eczema etc.
Outcomes
Primary Outcomes
REDUCTION IN SIGN AND SYMPTOMS OF VIPADIKA
Time Frame: 30 days
Secondary Outcomes
- COST EFFECTIVE TREATMENT(30 DAYS)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT06233864Sun Yat-sen University63
Active, not recruiting
Phase 2
Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 SyndromePost-COVID ME/CFSNCT05697640Charite University, Berlin, Germany104
Withdrawn
Phase 2
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyMetastatic Cervical CancerNCT05614453Australia New Zealand Gynaecological Oncology Group
Recruiting
Phase 2
Perioperative Treatment of Hepatoid Adenocarcinoma of StomachNCT06992362Peking University Cancer Hospital & Institute30
Recruiting
Phase 2
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersAdenoid Cystic CarcinomaNCT06805617Glenn J. Hanna35